Why is Concord Drugs falling/rising?

As of 14-Jul, Concord Drugs Ltd is experiencing a price increase, currently at Rs. 67.00, reflecting a rise of Rs. 2.79 or 4.35%. The stock has reached a new 52-week high today and has shown strong performance, gaining 33.25% over the last six days. In terms of returns, Concord Drugs has outperformed the Sensex significantly, with a 1-week return of +26.73% compared to the Sensex's -1.42%, and a remarkable 118.24% return over the past month against the Sensex's +1.40%. Despite this positive momentum, there are concerns regarding a decline in delivery volume, which has fallen by 44.06% against the 5-day average, indicating a potential decrease in investor participation.
Broader Market Context: The stock's impressive performance stands in stark contrast to the broader market, as it has consistently outperformed the Sensex over various time frames, including a 73.40% return over the past year compared to the benchmark's 2.15%. This strong performance is supported by attractive valuations, with the stock trading at a discount to its peers and a favorable enterprise value to capital employed ratio. However, it is important to note that while the stock has generated significant returns, its profits have decreased by 13% over the past year, which may raise concerns among investors about sustainability in the long term.